Millions of Americans struggling with depression could benefit from the active ingredient in magic mushrooms, new research suggests. However, approval of such treatments will depend on the U.S. Food and Drug Administration ( FDA ).
Roughly one in 10 American adults suffer from a depressive illness each year, according to Johns Hopkins Medicine, while one in four suffer from a diagnosable mental health disorder. Previous research has suggested that psilocybin—the active ingredient in magic mushrooms—may offer effective relief against major depressive disorder symptoms, with a short, two-dose treatment course lasting for up to a year.
While psychotherapy has shown promise for treating a range of mental health disorders and addictions, psilocybin-assisted therapy has not yet been given the greenlight by the FDA.
That doesn’t mean they aren’t considering it. Several breakthrough therapy designations have been granted for psilocybin in the treatment of resistant depression—that is, depression that does not respond to at least two different types of antidepressants—and a broader approval may be on the horizon. But as this milestone decision approaches, how many people actually stand to benefit from this kind of treatment? A photo shows magic mushrooms next to medication. If approved, new treatments featuring the active ingredient in magic mushrooms could help millions of people struggling with depression, new research suggests. In a new study from Emory University, the University of Wisconsin-Madison, and UC Berkeley, researchers set out to investigate the potential demand for psilocybin-assisted therapy for depression in the United States.
By combining data on depression prevalence—based on national surveys—with eligibility criteria for recent landmark clinical psychotherapy trials, the team determined that between 56 and 62 percent of those currently receiving treatment for depression—that is, 5.1 to 5.6 million Americans—could qualify for psilocybin therapy if it is approved.
"Our findings suggest that if the FDA gives the green light, psilocybin-assisted therapy has the potential to help millions of Americans who suffer from depression" Syed Fayzan Rab, an Emory MD candidate and the study’s lead author, said in a statement. "This underscores the importance of understanding the practical realities of rolling out this novel treatment on a large scale."
Rab added that […]
Depression: Five Million Americans May Benefit From Psychedelic Therapy
